drug

NBI-98854

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Neurocrine Biosciences
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
Tardive DyskinesiaTardive Dyskinesia

Trials

3
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
NCT01688037Phase 2Completed
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
NCT01393600Phase 2Completed
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
NCT01267188Phase 2Completed

KOLs & investigators

2
Christopher O'Brien, MD
Chris O'Brien, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Neurocrine Biosciences
company
trial
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
PHASE2
trial
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
PHASE2
trial
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
PHASE2
trial
indication
Tardive Dyskinesia
indication
Tardive Dyskinesia
indication
KOL
Christopher O'Brien, MD
KOL score —
person
Chris O'Brien, MD
KOL score —
person